As a novel galectin-3 inhibitor, HH1-1 exerts antitumor activity against pancreatic cancer by blocking the galectin-3/EGFR/AKT/FOXO3 signaling pathway (Yao et al., 2019). Here, LGALS3 is linked to familial pancreatic carcinoma.